Schrodinger

Yahoo Finance • 2 days ago

How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing... Full story

Yahoo Finance • 7 days ago

My Top 3 Biotech Stocks for May 2026

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billio... Full story

Yahoo Finance • 9 days ago

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Quick Read Dislocation between share price and product progress is exactly the kind of setup retail investors should scan for. Here are seven healthcare AI stocks trading under $50 where the bull case is grounded, not hype. The analyst wh... Full story

Yahoo Finance • last month

What’s Schrodinger Inc (SDGR) Working Out with Anthropic?

Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The presentation covered the company’s str... Full story

Yahoo Finance • last month

How The Schrödinger (SDGR) Narrative Is Shifting With Hosted Software And Lower Price Targets

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Schrödinger’s fair value estimate has been trimmed from US$23.50 to US$21.38, a move that lines up... Full story

Yahoo Finance • 3 months ago

Schrödinger targets 10%-15% ACV growth through accelerated hosted transition and platform innovation

Earnings Call Insights: Schrödinger (SDGR) Q4 2025 MANAGEMENT VIEW * CEO Ramy Farid stated that Schrödinger "is the leader in advancing and deploying computational methods for molecular discovery," emphasizing the company's differentia... Full story

Yahoo Finance • 3 months ago

Lowest Quant ranked small-cap stocks with positive EPS surprises

[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises ranked according to their lowest Seeking... Full story

Yahoo Finance • 3 months ago

Nvidia Earnings Slam Into Market With No Patience for AI Hiccups

(Bloomberg) — Nvidia Corp.’s earnings report on Wednesday afternoon comes at a critical time for the US stock market with investors increasingly nervous about the outlook for artificial intelligence. While most Wall Street pros are antici... Full story

Yahoo Finance • 5 months ago

Hasbro And 2 Other Stocks That May Be Priced Below Their Estimated Value

As the U.S. stock market navigates a holiday-shortened week, major indices like the Dow Jones, S&P 500, and Nasdaq have seen slight declines following a previous upward trend. In this fluctuating environment, identifying stocks that may be... Full story

Yahoo Finance • 5 months ago

3 Stocks Estimated To Be Priced Below Value In December 2025

As the major stock indexes in the United States continue to log weekly gains, with the S&P 500, Dow Jones Industrial Average, and Nasdaq all showing positive momentum over a holiday-shortened week, investors remain keenly focused on identi... Full story

Yahoo Finance • 5 months ago

BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price target. BofA stated this move is a result of... Full story

Yahoo Finance • 5 months ago

Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story

Yahoo Finance • 5 months ago

3 Stocks Estimated To Be Trading Below Intrinsic Value By At Least 41.3%

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, major indices like the S&P 500 and Dow Jones Industrial Average are nearing record highs, reflecting investor optimism. In this bu... Full story

Yahoo Finance • 7 months ago

AI in Biotechnology Market to Reach $11.4 Billion by 2030

BCC Research LLC “BCC Research analyzes how AI-driven discovery tools, predictive analytics, and scalable cloud platforms are transforming biotechnology's future.” Boston, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is... Full story

Yahoo Finance • 9 months ago

Schrodinger downgraded at Citi after clinical program exit

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Citi downgraded Schrodinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a... Full story

Yahoo Finance • 9 months ago

Schrödinger discontinues leukemia drug after patient deaths

NEW YORK - Schrödinger, Inc. (NASDAQ:SDGR), a $1.46 billion market cap biotech company with a strong balance sheet showing more cash than debt, announced Thursday it has discontinued the clinical development program for SGR-2921, its CDC7... Full story

Yahoo Finance • 9 months ago

Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts

Investing.com - Barclays initiated coverage on Schrodinger (NASDAQ:SDGR) with an Overweight rating and a $25.00 price target on Thursday. The stock, currently trading at $19.84 with a market capitalization of $1.46 billion, has shown volat... Full story

Yahoo Finance • 10 months ago

Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program

Earnings Call Insights: Schrödinger, Inc. (SDGR) Q2 2025 MANAGEMENT VIEW * CEO Ramy Farid highlighted "very solid progress in the first half of 2025" with total revenue of $54.8 million in the second quarter, a 16% increase year-over-y... Full story

Yahoo Finance • 10 months ago

Schrodinger stock maintains Buy rating at Citi on Ajax collaboration

Investing.com - Citi has reiterated a Buy rating and $39.00 price target on Schrodinger (NASDAQ:SDGR) following the company’s announcement of an expanded research collaboration with Ajax Therapeutics. According to InvestingPro data, this t... Full story

Yahoo Finance • 10 months ago

Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration

NEW YORK/CAMBRIDGE - Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR), a $1.56 billion market cap biotech company with robust revenue growth of 22% over the last twelve months, announced Thursday they are expanding their exclusi... Full story